A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
This study is testing different combinations of targeted cancer medications, including Lorlatinib, to help patients with specific types of advanced lung cancer. Researchers want to find safer and more effective treatment options when previous therapies have stopped working.
Adults aged 18 and older with advanced non-small cell lung cancer involving specific ALK or ROS1 gene changes may join. Participants must have cancer that progressed on previous targeted therapies and meet general health requirements.
Participants will receive combinations of study medications and have regular check-ups and scans to monitor their tumors and overall health. Your care team will closely watch you for any side effects throughout the process.
The study is currently taking place in Boston, Massachusetts, and its status is active. Please reach out to the study team to confirm the current enrollment details.
- 1Evaluates combinations of targeted medications for advanced lung cancer
- 2Designed for patients whose cancer has specific ALK or ROS1 gene changes
- 3Requires regular monitoring with scans and health checks
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.